A Kansas City, Kan., startup is taking steps toward drug development with the launch of a clinical trial for a new ADHD medication.
Cingulate Therapeutics is building out its leadership team as it launches an early-stage trial of CTX-1301, one of two ADHD medications the company is developing.
CTX-1301 uses a time-release technology developed by Glasgow-based BDD. It releases a stimulant medication in three phases throughout the day, minimizing the “afternoon crash” experienced with many existing…
A Kansas City, Kan., startup is taking steps toward drug development with the launch of a clinical trial for a new ADHD medication.
Cingulate Therapeutics is building out its leadership team as it launches an early-stage trial of CTX-1301, one of two ADHD medications the company is developing.
CTX-1301 uses a time-release technology developed by Glasgow-based BDD. It releases a stimulant medication in three phases throughout the day, minimizing the “afternoon crash” experienced with many existing…
